


(S,R,S)-AHPC-C1-NH2

| | |
|--------------------|---|
| Cat. No.: | HY-138861 |
| CAS No.: | 2010986-20-4 |
| Molecular Formula: | C ₂₄ H ₃₃ N ₅ O ₄ S |
| Molecular Weight: | 487.61 |
| Target: | E3 Ligase Ligand-Linker Conjugates |
| Pathway: | PROTAC |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | (S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology ^[1] . |
| IC ₅₀ & Target | VHL |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. *Comput Struct Biotechnol J*. 2019;17:160-176. Published 2019 Jan 25.
- [2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol*. 2020;27(8):998-985.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA